Abeona raises $92M in follow-on

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) raised $92 million through the sale of 5.8 million shares at $16 in a follow-on underwritten by Jefferies, RBC Capital Markets, Cantor Fitzgerald, FBR Capital Markets, H.C. Wainwright, JonesTrading Institutional Services and Maxim Group. The price is a 4% discount to Abeona's close of $16.70 on Oct. 16 before it proposed the offering after market hours. The figures include the sale of a 750,000 share overallotment on Oct. 19.

Abeona is conducting a pivotal Phase I/II trial of ABO-102 (AAV-SGSH) to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome). ABO-102 is an adeno-associated viral serotype 9 (AAV9) vector that delivers the N-sulfoglucosamine sulfohydrolase (SGSH; HNS) gene...